Sector News

Santen establishes UK subsidiary

November 5, 2014
Life sciences
Japanese drugmaker Santen has set up shop in the UK to help push its recently acquired glaucoma franchise from Merck & Co into the market.
 
The group said it has established a UK subsidiary to promote products such as Saflutan and Cosopt – purchased from Merck back in May for $600 million plus royalties – and help strengthen its footprint in Europe.
 
“The establishment of our own subsidiary in the UK is an important step in achieving our long term corporate vision to become a specialised pharmaceutical company with a global presence”, said Masamichi Sato, Head of Santen European Group and President of Santen Holding EU BV.
 
The move will allow the group to provide its complete portfolio of products throughout Europe, and the launch of commercial teams in other European countries such as Spain, Portugal or Benelux “is expected within the next few months,” he added.
 
By Selina McKee
 
Source: Pharma Times
 

Related News

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]